Novel nuclear medicine approach shows promise for treating wide array of cancerous tumors
Share

IMAGE: 225Ac-proteus-DOTA hapten can be targeted in vivo to GPA33-expressing human colorectal cancer xenografts using anti-GPA33-DOTA-PRIT, with minimal radioactive uptake in critical radiosensitive tissues such as blood and kidney. In addition,… view more 

Credit: SM Cheal et al., Memorial Sloan Kettering Cancer Center, New York, NY.

PHILADELPHIA – A novel nuclear medicine approach is showing great promise for precision treatment of solid tumors in many types of cancer–including lung, breast, pancreas and ovarian in adults and glioma, neuroblastoma and sarcoma in children. The research was presented today at the SNMMI 2018 Annual Meeting, June 23-26 in Philadelphia.

In 2017, researchers from Memorial Sloan Kettering Cancer Center developed a novel approach to pretargeted radioimmunotherapy (DOTA-PRIT) that demonstrated preclinically, complete responses, including cures, in several solid tumor types using the beta-emitting lutetium-177 (177Lu)-DOTA-hapten. In the research presented today, the researchers expanded the DOTA-PRIT approach to actinium-225 (225Ac), an alpha-emitting isotope.

“Targeted alpha radiotherapy has shown considerable promise for patients, especially for those with advanced castration-resistance prostate cancer,” said Steven M Larson, MD and Sarah M. Cheal, PhD, of the Program in Molecular Pharmacology and Department of Radiology at Memorial Sloan Kettering Cancer Center in New York. “By combining DOTA-PRIT with 225Ac-proteus-DOTA

read more...


Article originally posted at
www.eurekalert.org

Click here for the full story


CategoryAggregator News

© 2017 - LIFE EXTENSION ADVOCACY FOUNDATION
Privacy Policy / Terms Of Use

Powered by MMD